Big Pharma Sharma

Big Pharma Sharma

Share this post

Big Pharma Sharma
Big Pharma Sharma
ASH 2024 | Part 1: Miltenyi and Galapagos Aim Big in CAR-T, but Gaps Remain

ASH 2024 | Part 1: Miltenyi and Galapagos Aim Big in CAR-T, but Gaps Remain

Big Pharma Sharma's avatar
Big Pharma Sharma
Dec 09, 2024
∙ Paid
1

Share this post

Big Pharma Sharma
Big Pharma Sharma
ASH 2024 | Part 1: Miltenyi and Galapagos Aim Big in CAR-T, but Gaps Remain
1
Share
a person holding a baseball bat
Photo by Norbert Braun on Unsplash

It’s time for the annual ASH meeting, always a showcase for cutting-edge clinical data in competitive areas like blood cancers and hemoglobinopathies.

The weekend slate at ASH did not disappoint, featuring several updates in the CAR-T space. Notably, two programs from less well-known players caught my attention, both employing fresh-in/fresh-out manufacturing (non-cryopreserved starting material and final product). While intriguing, these approaches leave lingering questions about their scalability and commercial potential.

Miltenyi Biomedicines’ Zamto-Cel

First up is Miltenyi’s little-known biomedicines division, with Zamto-Cel, the company’s CD19/20 CAR-T in the pivotal P2 DALY II USA study in 3L+ DLBCL. Miltenyi Biotec is obviously one of the leaders in the cell therapy manufacturing device space. Many cell therapy companies utilize the CliniMACS Prodigy system. Miltenyi Biomedicines is a subsidiary of the device giant focused on advancing largely CAR-T programs, although Zamto-Cel is by far the most advanced.

In the interim P2 data readout, Zamto-cel demonstrated an efficacy profile in line with YESCARTA’s, but with lower incidences of CRS and ICANS. Two-targets are maybe showing to better than one, with the median PFS registering at 9 months (vs. ~6 months in YESCARTA’s ZUMA-1), but it is still too early to tell whether the additional targeting is leading to an efficacy advantage.

Zamto-Cel was pioneered by Dr. Nirav Shah from Medical College of Wisconsin, who conducted much of the early work for this Fresh-in/Fresh-out approach in single-center P1 studies. The key differentiator for this approach is the fac that there is no cryopreservation utilized in this process, which Miltenyi and Shah say enables a “true 14-day turnaround time” and minimizes the need for bridging therapy.

If you would like to get access to the rest of this post as well as all my posts, please consider joining your colleagues and becoming a paid subscriber for less than $10/month

Keep reading with a 7-day free trial

Subscribe to Big Pharma Sharma to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Big Pharma Sharma LLC
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share